Renaissance Technologies
NEUP

Renaissance Technologies’s Neuphoria Therapeutics NEUP Stock Holding History

Renaissance Technologies’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Buy
+25,500
New +$123K ﹤0.01% 2966

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies's NEUP Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Neuphoria Therapeutics (NEUP) in Q2 2026: 25,500 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #2966 among its holdings.

13 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Renaissance Technologies held 25,500 shares of Neuphoria Therapeutics worth $111K as of Q2 2026.
  • Neuphoria Therapeutics was a new Renaissance Technologies position in Q2 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2966 holding.
  • 13 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.